Kiniksa Pharmaceuticals Ltd. (KNSA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Kiniksa Pharmaceuticals L...

    NASDAQ: KNSA · Real-Time Price · USD
    35.71
    0.20 (0.56%)
    At close: Sep 05, 2025, 3:59 PM
    35.95
    0.67%
    After-hours: Sep 05, 2025, 06:26 PM EDT

    Kiniksa Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 423.24M 270.26M 220.18M 38.54M
    Cost of Revenue
    		 60.91M 56.52M 46.97M 9.1M
    Gross Profit
    		 362.33M 213.74M 173.21M 29.44M
    Operating Income
    		 -45.62M -25.2M 7.37M -156.64M
    Interest Income
    		 n/a 8.54M 1.25M 97K
    Pretax Income
    		 -36.15M -16.65M 11.03M -156.54M
    Net Income
    		 -43.19M 14.08M 183.36M -157.92M
    Selling & General & Admin
    		 168.01M 129.43M 97.95M 85.95M
    Research & Development
    		 111.62M 76.1M 65.49M 99.3M
    Other Expenses
    		 128.31M 33.41M 1.25M 835K
    Operating Expenses
    		 407.94M 238.93M 163.44M 186.08M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 468.86M 295.45M 210.41M 195.18M
    Income Tax Expense
    		 7.04M -30.74M -172.34M 1.39M
    Shares Outstanding (Basic)
    		 71.42M 70.06M 69.38M 68.58M
    Shares Outstanding (Diluted)
    		 71.42M 71.92M 70.42M 68.58M
    EPS (Basic)
    		 -0.6 0.20 2.64 -2.3
    EPS (Diluted)
    		 -0.6 0.20 2.60 -2.3
    EBITDA
    		 -45.62M -22.86M 9.77M -154.28M
    EBIT
    		 -45.62M -25.2M 11.03M -156.64M
    Depreciation & Amortization
    		 n/a 2.34M 4.22M 4.09M

    Add to Watchlist